IRulya Therapeutics Inc. (IRLA)
IRLANASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$41.12
+2.67 (+6.94%) today
Regular session, Nov 18, 3:01 PM ET
- Market cap
- $445.80m
- P/E
- –
- EPS, last 4 quarters
- $-111.23
- Dividend yield
- –
- Day range
- $37.94 to $42.73
- 52-week range
- $15.10 to $909.98
- Average volume
- –
- Previous close
- $38.45
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $77.00, +87.3% from here
Earnings
next estimate $-0.9700Next report
Dec 2025
–
Mar 2026
–
Jun 2026
+63.0%
Sep 2026
-33.3%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Raymond James Initiates Coverage of Quince Therapeutics at OutperformFintel · Oct 9, 2026
- Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a BuyFintel · Sep 24, 2026
- Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict RTTNews · Jul 14, 2026
- Quince Therapeutics (QNCX) Price Target Increased by 100.00% to 81.60Fintel · May 14, 2026
- Quince Therapeutics (QNCX) Price Target Increased by 900.00% to 40.80Fintel · Apr 27, 2026
- Quince Therapeutics Stock Climbs 8% Over Payment Of $5.5 Mln To Settle EIB Loan RTTNews · Mar 30, 2026
- Quince Therapeutics Exploring Strategic Alternatives; Stock Soars RTTNews · Feb 10, 2026
- D. Boral Capital Maintains Quince Therapeutics (QNCX) Buy RecommendationFintel · Dec 15, 2025
The company
IRulya Therapeutics Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a clinical study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b clinical study in PH-ILD is ongoing, and a Phase 2 clinical study in SAPH is anticipated to begin in the fourth quarter of 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- quincetx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.